Table 3.

Studies with qualitative/quantitative analysis in regard of WHO complexes

		Quantitative analysis		Qualitative analysis
WHO complex	Factor	Association found	No association found	Non-adherent patients	All patients
Condition	Comorbidity	Westborg et al. [55]	McGrath et al. [52]1, Polat et al. [15]	Droege et al. [14], Gillies et al. [49], Heimes et al. [50], Krüger Falk et al. [51], Nunes et al. [53], Polat et al. [15], Weiss et al. [16]	Polat et al. [15]2
	Fellow eye	Ehlken et al. [48]3	Polat et al. [15]
	Lower VA at baseline	Ehlken et al. [17], Oishi et al. [54], Polat et al. [15], Westborg et al. [55]			Baxter et al. [57]
	VA change (subj. or obj.)	Oishi et al. [54], Polat et al. [15], Weiss et al. [16], Ziemssen et al. [56]		Boulanger-Scemama et al. [13], Gillies et al. [49], McGrath et al. [52]4, Nunes et al. [53], Polat et al. [15], Weiss et al. [16], Westborg et al. [55]	Boyle et al. [2], Sii et al. [58], Kostadinov et al. [59], Mueller et al. [20]
Health system	Center-dependent	Ehlken et al. [17], Heimes et al. [50], Westborg et al. [55], Ehlken et al. [48]		Krüger Falk et al. [51], Nunes et al. [53], Polat et al. [15], Weiss et al. [16]
Patient	Anxiety, fear		Droege et al. [14]5	Polat et al. [15]	Boyle et al. [2], Droege et al. [60], Müller et al. [61], Senra et al. [62], Sii et al. [58], Kostadinov et al. [59]
	Motivation, knowledge, expectations			Droege et al. [14], Krüger Falk et al. [51], Weiss et al. [16], Westborg et al. [55]	Boyle et al. [2], Müller et al. [61], Sii et al. [58]
Socio-economic	Education	Polat et al. [15]
	Age	Boulanger-Scemama et al. [13], Ehlken et al. [17], Oishi et al. [54]6, Polat et al. [15], Ehlken et al. [48]
	Travel, distance to treatment	Boulanger-Scemama et al. [13], McGrath et al. [52], Polat et al. [15]		Boulanger-Scemama et al. [13], Heimes et al. [50], Nunes et al. [53], Polat et al. [15], Weiss et al. [16]	Droege et al. [60]
	Financial burden, reimbursement			Boulanger-Scemama et al. [13], McGrath et al. [52], Polat et al. [15], Weiss et al. [16], Ziemssen et al. [56]	Kostadinov et al. [59]
Therapy	Type of drug	Westborg et al. [55]7	Curtis et al. [47]7, Gillies et al. [49]7
	Fear of adverse events			Atchison et al. [46], Krüger Falk et al. [51], Weiss et al. [16], Westborg et al. [55], Ziemssen et al. [56]	Boyle et al. [2], Droege et al. [60], Kostadinov et al. [59], Mueller et al. [20]
	Treatment regimen, follow-up burden	Ehlken et al. [48]		Boulanger-Scemama et al. [13], Krüger Falk et al. [51]	Droege et al. [60], Müller et al. [61], Senra et al. [62]

¹Comorbidity was associated with less non-adherence in this study from Australia

²Comorbidity identified as relevant in interviews, but not identified as factor in statistical analysis

³Treatment-dependent AMD in fellow eye associated with higher risk for NA

⁴Patients with a subjective good vision had a higher risk of stating that IVT is not needed despite recommendation from their attending ophthalmologist

⁵No correlation with number of injections was found in this study

⁶In this study, lower age was associated with non-adherence, although this was not true in bivariate analysis

⁷[55]: More NA in patients treated with ranibizumab than aflibercept. [47, 49]: No difference between ranibizumab and bevacizumab or aflibercept and ranibizumab